our study aim to determine whetherexpression of Fcï?§RIII on peripheral blood mononuclear cells (NK-Tcells& monocytes) and its polymorphism determines the response to treatment to rituximab in pemphigus.
Not Applicable
- Conditions
- Health Condition 1: L100- Pemphigus vulgaris
- Registration Number
- CTRI/2019/04/018812
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age 1.More than 18 years. 2. Patients of pemphigus vulgaris or foliaceus who has received rituximab (rheumatoid arthritis protocol i.e. 2 doses each dose of1000mg 2 weeks apart. 3. Received second dose of a cycle of rituximab more than 9 months before inclusion in the study.
Exclusion Criteria
1.Inability to give valid consent.
2.Patients who had active viral infection within 4 weeks before inclusion in the study.
3.Known case of hematologic or solid organ malignancy.
4.Recent vaccinations (within 3 months before inclusion in the study).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method